Trogarzo

CLINICAL RESEARCH UPDATE by Jeffrey T. Kirchner, DO, AAHIVS, AAHIVM Chief Medical Officer January 28, 2020

Highlights of Presecribing Information: Trogarzo

Ibalizumab, a recombinant humanized monoclonal antibody, represents the first novel agent for HIV-1 management in over a decade and is the first monoclonal antibody for the treatment of MDR HIV-1 infection in combination with other forms of antiretroviral therapy in heavily treatment-experienced adults who are failing their current antiretroviral regimen. Ibalizumab demonstrates a novel mechanism

Clinical review of Ibalizumab-uiyk (Trogarzo, Theratechnologies)

Results From Trogarzo® IV Push Administration Study as presented at CROI

Currently, there are a number of combination drugs developed against various viral infections to arrest the activity of same or different viral macromolecules at multiple stages of its life cycle; among which majority are targeted to interfere with the replication of viral genome.

Monoclonal antibodies (mAbs) as alternatives or more often as complementary to the conventional antimicrobials have been developed for the management of infectious conditions for the past two decades. These pharmacotherapeutic strategies are inevitable as the burden of antimicrobial resistance is far-reaching in recent times. MAbs are part of the targeted pharmacotherapy armamentarium with a high

Case reports of sustained HIV-1 remission, new drug approvals, and resistance testing provide patients with potential novel therapy approaches.

2018 was a record setting year for new drug approvals by the FDA. This article highlights some of the drugs that have new mechanisms of action or have indications that have not previously been available.